Skip to main content
. Author manuscript; available in PMC: 2016 Jan 4.
Published in final edited form as: JAMA. 2014 Jul 2;312(1):48–56. doi: 10.1001/jama.2014.7192

Figure 1. Donor Leukocyte Engraftment After Hematopoietic Stem Cell Transplantation (HSCT).

Figure 1

Eleven patients who were still receiving immunosuppression medication (sirolimus) are shown in panels A (myeloid) and C (lymphoid). Fifteen patients who later discontinued immunosuppression medication are shown in panels B and D. The orange lines and data points represent values after patients ceased immunosuppression medication. At the very early time points, eg, 1 month after transplant when patients began to shows signs of white blood cell engraftment, there often were not sufficient numbers of leukocytes for chimerism analysis. Thus not all time points include all 26 data points. At later time point, some patients could not travel back at the half-year marks (eg, 2.5, 3.5, or 4.5 year) for chimerism analysis; thus, there are fewer data points at those times.